x

Search for a networks

* (*) mandatory field

GRIPHON 2 : A multicenter, double-blind, placebo-controlled Phase 3 study to demonstrate the efficacy and safety of ACT-293987 in patients with pulmonary arterial hypertension (coordination)

  • Type of network : Multinational clinical trials
  • Geographic coverage : Global
  • Funding body(ies) : ACTELION PHARMACEUTICALS LTD. 
  • Sponsor : Frey
  • Website
  • Coordinator of multinational clinical trial

  • Dr Aline FREY
  • Actelion Pharmaceuticals Ltd.
  • Gewerbestrasse 16
  • 914123 ALLSCHWIL
  • SWITZERLAND
  • More information
  • Phone  : 0041 (0)61 565 65 65
  • Fax  : 0041 (0)61 565 65 00
  • Website
Last update: May 2017

Participants

Additional information

The documents contained in this web site are presented for information purposes only. The material is in no way intended to replace professional medical care by a qualified specialist and should not be used as a basis for diagnosis or treatment.